ScreenerHero

PDSBPDS Biotechnology Corp.

NAS · US · Healthcare · Biotechnology · pdsbiotech.com
0.2185USD+8.87%Mkt Cap: 12.23M $P/E: —

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap12.23M $
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.50M $
Revenue/Share—
Last Price0.2185 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS70465T1079
Valuation
P/E (Trailing)—
P/E (Forward)-0.51
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.24
EPS (TTM)-0.67
EPS (Forward)-0.41
52W Range
0.19522% of range1.550
52W High1.550 USD
52W Low0.1952 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-372.85%
ROA-113.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.75M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity1.83
Current Ratio—
Quick Ratio—
Book Value/Sh0.1690 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 18, 2019
Splits
Last Split1:20
Split DateMar 18, 2019
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.750 USD
Upside (mean)+2531.6%
Target Range4.500 USD – 7.000 USD
$4.500+2531.6% to mean$7.000
# Analysts2
Ownership
Shares Out.55.97M
Float54.40M
Insiders1.51%
Institutions13.86%
Short Interest
Short Ratio6.9d
Short % Float3.40%
Short % Out.3.28%
Shares Short1.83M
Short (prev mo.)1.34M
Technical
SMA 500.7215 (-69.7%)
SMA 2000.8500 (-74.3%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)1.80M
Avg Vol (10d)5.05M
Technical Indicators
RSI (14)19.3
MACD-0.1580
MACD Signal-0.1184
MACD Hist.-0.0397
BB Upper1.016 USD
BB Middle0.5418 USD
BB Lower0.0679 USD
BB Width174.94%
ATR (14)0.0678 USD
Vol Ratio (20d)1.20x